Bioequivalence study of a fixed dose combination of nitazoxanide and ofloxacin in Indian healthy volunteers

被引:0
作者
Agarwal, Sangita [1 ]
Solomon, W. D. Sam [1 ]
Gowda, K. Veeran [1 ]
Selvan, P. Senthamil [1 ]
Ghosh, Debotri [1 ]
Sarkar, Amlan Kand [1 ]
Chattaraj, Tapas Kumar [1 ]
Pal, Tapan Kumar [1 ]
机构
[1] Jadavpur Univ, Bioequivalence Study Ctr, Dept Pharmaceut Technol, Kolkata 700032, W Bengal, India
来源
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH | 2007年 / 57卷 / 10期
关键词
antibiotics; antiparasitic drugs; CAS; 55981-09-4; 82419-36-1; nitazoxanide; active metabolite; bioavailability; bioequivalence; fixed dose combination; ofloxacin;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Objective. The pharmacokinetics of nitazoxanide (CAS 55981-09-4) and ofloxacin (CAS 82419-36-1) has been extensively evaluated in adult human volunteers individually after oral administration of tablet formulation. However, no published data is available regarding the combined pharmacokinetics and bioavailability of this particular fixed dose combination. In light of the above, a clinical study was designed to evaluate the bioequivalence of two fixed dose combination (FDC) products of two manufacturers containing nitazoxanide 500 mg and ofloxacin 200 mg in healthy Indian male volunteers. Methods: 24 healthy male volunteers (age 25 +/- 4.6 years; weight 74.5 +/- 7.87 kg) were enrolled in this study. Each subject received a Test fixed dose combination and a Reference fixed dose combination formulation in a randomized, single dose, fasting state, two period, crossover study design with a 1-week washout period between the doses. Extraction of the drugs from the plasma was carried out by precipitation method. Analysis of tizoxanide (active metabolite of nitazoxanide) and ofloxacin from plasma samples was done by a simple and sensitive HPLC method using IN detection developed in our laboratory. An analysis of variance was performed on the pharmacokinetic parameters C-max, AUC(0-t), AUC(0-infinity) using general linear model (GLM) procedures in which sources of variation were subject, formulation, period. Results. The results of this investigation indicated that there were no statistically significant differences between the two products in either the mean concentration-time profiles or in the obtained pharmacokinetic parameters. 90% confidence limits for the log-transformed data of C-max, AUC(0-t), AUC(0-infinity). were within the acceptable range of 0.80-1.25. Conclusion: Thus, these findings clearly indicate that the two products are bioequivalent in terms of rate and extent of drug absorption. Both the preparations were well tolerated with no adverse reactions seen throughout the study.
引用
收藏
页码:679 / 683
页数:5
相关论文
共 50 条
  • [21] Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg) Tablets in Healthy Volunteers
    Jung, Sang-hoon
    Chae, Jung-woo
    Song, Byung-jeong
    Kwon, Kwang-il
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2014, 13 (02): : 365 - 371
  • [22] Pharmacokinetic Properties and Bioequivalence of Two Sulfadoxine/Pyrimethamine Fixed-Dose Combination Tablets: A Parallel-Design Study in Healthy Chinese Male Volunteers
    Liu, Yan-Mei
    Zhang, Kanyin E.
    Liu, Yun
    Zhang, Hai-Chen
    Song, Yun-Xiao
    Pu, Hua-Hua
    Lu, Chuan
    Liu, Gang-Yi
    Jia, Jing-Ying
    Zheng, Qing-Si
    Zhu, Jian-Min
    Yu, Chen
    CLINICAL THERAPEUTICS, 2012, 34 (11) : 2212 - 2220
  • [23] Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations
    Panchagnula, R
    Singh, I
    Kaur, KJ
    Kaul, CL
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1999, 21 (09): : 625 - 628
  • [24] Bioequivalence study of two different tablet formulations of carvedilol in healthy volunteers
    Portolés, A
    Filipe, A
    Almeida, S
    Terleira, A
    Vallée, F
    Vargas, E
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2005, 55 (04): : 212 - 217
  • [25] Comparative bioavailability of two capsule formulations of ofloxacin in healthy volunteers after a single dose administration
    Oliveira, CF
    Dias, HB
    Ribeiro, W
    Poli, A
    Peixoto, AP
    Moraes, MEA
    Moraes, MO
    Bezerra, FAF
    Moreno, H
    Muscará, MN
    de Nucci, G
    CLINICAL RESEARCH AND REGULATORY AFFAIRS, 1999, 16 (1-2) : 29 - 40
  • [26] Pharmacokinetics and bioequivalence study of clindamycin hydrochloride formulations after single-dose administration in healthy Chinese male volunteers
    Li, Jing
    Wang, Na
    Zhang, Zun-Jian
    Tian, Yuan
    Tang, Weiguo
    Chen, Yun
    ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2008, 58 (07): : 358 - 362
  • [27] Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers
    Abhyankar, Dhiraj
    Shedage, Ashish
    Gole, Milind
    Raut, Preeti
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2017, 32 (06): : 360 - 366
  • [28] Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects
    Grill, Simon
    Bruderer, Shirin
    Sidharta, Patricia N.
    Antonova, Mariya
    Globig, Susanne
    Carlson, James
    Schultz, Armin
    Csonka, Denes
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (12) : 2424 - 2434
  • [29] Bioequivalence study of two losartan formulations administered orally in healthy male volunteers
    Bienert, Agnieszka
    Brzezinski, Rafal
    Szalek, Edyta
    Dubai, Vitali
    Grzeskowiak, Edmund
    Dyderski, Stanislaw
    Drobnik, Leon
    Wolc, Anna
    Olejniczak-Rabinek, Magdalena
    ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, 2006, 56 (11): : 723 - 728
  • [30] A randomized single-dose, two-period crossover bioequivalence study of two fixed-dose Paracetamol/Orphenadrine combination preparations in healthy volunteers under fasted condition
    Cheah, Kit Yee
    Mah, Kar Yee
    Pang, Lai Hui
    Ng, Shi Min
    Wong, Jia Woei
    Tan, Siew Siew
    Tan, Hong Zhe
    Yuen, Kah Hay
    BMC PHARMACOLOGY & TOXICOLOGY, 2020, 21 (01)